Related Articles

Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease

Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study

January 2008 US Myozyme Supply Update In April 2007, Genzyme implemented measures to manage the limited supply of Myozyme® (alglucosidase alfa) in the United States in order to ensure uninterrupted treatment for as many patients as possible. Since April, both the...

Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement

October Update on the US Myozyme® Supply

Rehabilitation Management of Pompe Disease

Dear All, The AMDA, UPF, NORD, and Genzyme attended a stakeholder’s meeting on August 29, 2007 at the FDA to discuss the current Myozyme supply situation. Following is a brief report on the meeting. Representatives from Genzyme included individuals from the executive,...

Therapy -- It's Here, and Free Letters to the Editor 15 August 2007 The Wall Street Journal The Wall Street Journal - Print and Online CTGWSJ A11 Genzyme is working closely and constructively with the Food and Drug Administration to obtain approval of the large-scale...

US Myozyme® Supply Update July 25, 2007

POMP/US/P164/06/07 Genzyme Pompe Program Update June 2007 Genzyme would like to take this opportunity to provide a brief update to the Pompe patient community regarding the US supply of Myozyme® (alglucosidase alfa). As planned, Genzyme submitted the necessary...